The Streptococcus pyogenes vaccine landscape

被引：46

作者：

Walkinshaw, Donald R. ^{[1
]}

Wright, Meghan E. E. ^{[1
]}

Mullin, Anne E. ^{[1
]}

Excler, Jean-Louis ^{[2
]}

Kim, Jerome H. ^{[2
,3
,4
]}

Steer, Andrew C. ^{[3
,5
,6
]}

机构：

[1] Shift Hlth, Toronto, ON, Canada

[2] Int Vaccine Inst, Seoul, South Korea

[3] Strep Vaccine Global Consortium SAVAC Execut Comm, Seoul, South Korea

[4] Seoul Natl Univ, Seoul, South Korea

[5] Murdoch Childrens Res Inst, Melbourne, Australia

[6] Univ Melbourne, Melbourne, Australia

来源：

NPJ VACCINES | 2023年 / 8卷 / 01期

基金：

英国惠康基金;

关键词：

GROUP-A STREPTOCOCCUS; M PROTEIN VACCINE; IMMUNOGENICITY; SAFETY; IMMUNIZATION; STREPTINCOR; VOLUNTEERS; CHALLENGE; EFFICACY; DISEASE;

D O I：

10.1038/s41541-023-00609-x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recent efforts have re-invigorated the Streptococcus pyogenes (Group A Streptococcus) vaccine development field, though scientific, regulatory and commercial barriers persist, and the vaccine pipeline remains sparse. There is an ongoing need to accelerate all aspects of development to address the large global burden of disease caused by the pathogen. Building on over 100 years of S. pyogenes vaccine development, there are currently eight candidates on a product development track, including four M protein-based candidates and four candidates designed around non-M protein antigens. These candidates have demonstrated proof of concept for protection against S. pyogenes in preclinical models, one has demonstrated safety and immunogenicity in a Phase 1 trial and at least four others are poised to soon enter clinical trials. To maintain momentum, the Strep A Vaccine Global Consortium (SAVAC) was established to bring together experts to accelerate global S. pyogenes vaccine development. This article highlights the past, present and future of S. pyogenes vaccine development and emphasizes key priorities, and the role of SAVAC, in advancing the field.

引用

页数：6

共 43 条

[1]

[Anonymous], 2018, Seventy-first World Health Assembly: Geneva, 21-26 May. Resolutions and decisions annexes

[2] Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case [J].

Bensi, Giuliano ;

Mora, Marirosa ;

Tuscano, Giovanna ;

Biagini, Massimiliano ;

Chiarot, Emiliano ;

Bombaci, Mauro ;

Capo, Sabrina ;

Falugi, Fabiana ;

Manetti, Andrea G. O. ;

Donato, Paolo ;

Swennen, Erwin ;

Gallotta, Marilena ;

Garibaldi, Manuela ;

Pinto, Vittoria ;

Chiappini, Nico ;

Musser, James M. ;

Janulczyk, Robert ;

Mariani, Massimo ;

Scarselli, Maria ;

Telford, John L. ;

Grifantini, Renata ;

Norais, Nathalie ;

Margarit, Immaculada ;

Grandi, Guido .

MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (06)

[3] A brief review on Group A Streptococcus pathogenesis and vaccine development [J].

Castro, Sowmya Ajay ;

Dorfmueller, Helge C. .

ROYAL SOCIETY OPEN SCIENCE, 2021, 8 (03)

[4] Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice [J].

Cleary, PP ;

Matsuka, YV ;

Huynh, T ;

Lam, H ;

Olmsted, SB .

VACCINE, 2004, 22 (31-32) :4332-4341

[5] Streptococcus pyogenes Arginine and Citrulline Catabolism Promotes Infection and Modulates Innate Immunity [J].

Cusumano, Zachary T. ;

Watson, Michael E., Jr. ;

Caparon, Michael G. .

INFECTION AND IMMUNITY, 2014, 82 (01) :233-242

[6] New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci [J].

Dale, James B. ;

Penfound, Thomas A. ;

Chiang, Edna Y. ;

Walton, William J. .

VACCINE, 2011, 29 (46) :8175-8178

[7] Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics [J].

Davies, Mark R. ;

McIntyre, Liam ;

Mutreja, Ankur ;

Lacey, Jake A. ;

Lees, John A. ;

Towers, Rebecca J. ;

Duchene, Sebastian ;

Smeesters, Pierre R. ;

Frost, Hannah R. ;

Price, David J. ;

Holden, Matthew T. G. ;

David, Sophia ;

Giffard, Philip M. ;

Worthing, Kate A. ;

Seale, Anna C. ;

Berkley, James A. ;

Harris, Simon R. ;

Rivera-Hernandez, Tania ;

Berking, Olga ;

Cork, Amanda J. ;

Torres, Rosangela S. L. A. ;

Lithgow, Trevor ;

Strugnell, Richard A. ;

Bergmann, Rene ;

Nitsche-Schmitz, Patric ;

Chhatwal, Gusharan S. ;

Bentley, Stephen D. ;

Fraser, John D. ;

Moreland, Nicole J. ;

Carapetis, Jonathan R. ;

Steer, Andrew C. ;

Parkhill, Julian ;

Saul, Allan ;

Williamson, Deborah A. ;

Currie, Bart J. ;

Tong, Steven Y. C. ;

Dougan, Gordon ;

Walker, Mark J. .

NATURE GENETICS, 2019, 51 (06) :1035-+

[8] Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes [J].

De Amicis, Karine M. ;

de Barros, Samar Freschi ;

Alencar, Raquel E. ;

Postol, Edilberto ;

Martins, Carlo de Oliveira ;

Arcuri, Helen Andrade ;

Goulart, Cibelly ;

Kalil, Jorge ;

Guilherme, Luiza .

VACCINE, 2014, 32 (32) :4104-4110

[9] Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus [J].

Di Benedetto, Roberta ;

Mancini, Francesca ;

Carducci, Martina ;

Gasperini, Gianmarco ;

Moriel, Danilo Gomes ;

Saul, Allan ;

Necchi, Francesca ;

Rappuoli, Rino ;

Micoli, Francesca .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) :1-21

[10] Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes [J].

Edwards, RJ ;

Taylor, GW ;

Ferguson, M ;

Murray, S ;

Rendell, N ;

Wrigley, A ;

Bai, ZH ;

Boyle, J ;

Finney, SJ ;

Jones, A ;

Russell, HH ;

Turner, C ;

Cohen, J ;

Faulkner, L ;

Sriskandan, S .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (05) :783-790

← 1 2 3 4 5 →